OLD National Bancorp IN Has $1.84 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

OLD National Bancorp IN decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,718 shares of the biopharmaceutical company’s stock after selling 802 shares during the quarter. OLD National Bancorp IN’s holdings in Gilead Sciences were worth $1,840,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Tompkins Financial Corp raised its stake in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $26,000. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Rakuten Securities Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $33,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $40,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ:GILD opened at $66.95 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The company’s 50-day moving average price is $71.81 and its two-hundred day moving average price is $76.51. The firm has a market cap of $83.36 billion, a P/E ratio of 14.88, a P/E/G ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The firm had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the prior year, the business posted $1.67 earnings per share. Gilead Sciences’s quarterly revenue was down 3.7% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a $0.77 dividend. The ex-dividend date was Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. UBS Group lowered their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Mizuho lowered their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.